Teva Pharmaceutical Industries has entered into a definitive agreement to acquire Labrys Biologics, Inc., a privately-held biotechnology company focused on treatments for chronic and episodic migraine, for $200 million in cash and as much as $625 million in potential milestones.      Labrys has a range of investigational, approved and marketed treatments for migraine, cancer pain and chronic pain. Labrys is developing LBR-101, a fully humanized monoclonal antibody in Phase IIb trials for prevent...